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Abstract: Circulating tumor cells (CTCs) are rare cells that origi-
nate from a malignancy and circulate freely in the peripheral blood.
The ability to capture and study CTCs is an emerging field with
implications for early detection, diagnosis, determining prognosis
and monitoring of cancer, as well as for understanding the funda-
mental biology of the process of metastasis. Here, we review the
development and initial clinical studies with a novel microfluidic
platform for isolating these cells, the CTC-chip, and discuss its
potential uses in the study of lung cancer.
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For one hundred and forty years, we have known that thereare tumor cells circulating in the peripheral blood of
patients with cancer.1 The modern understanding of cancer
biology and the process of metastasis suggests that these
circulating cells play a vital role in forming metastatic dis-
ease.2 However, studying this cellular population has been
particularly challenging because their extreme rarity in com-
parison to hematologic cells (about 1 tumor cell per 1 billion
blood cells) has made them difficult to isolate. Over the past
decade, progress has been made in the field through the
introduction of several new technologies, most notably an
epithelial antibody-coated magnetic bead isolation system
that has allowed gross quantification of circulating tumor
cells (CTCs) from the blood of cancer patients and has been
useful in prognostication in patients with advanced breast,
colon, and prostate cancers.3–6 Here, we will summarize the
findings with a recently described microfluidic-based tech-
nology called the CTC-chip, that may make it possible to
expand CTC detection from a prognostic indicator to a
detection and surveillance tool as well as an invaluable
research adjunct.7,8
The CTC-chip technology is unique because its use of
microfluidics provides a platform by which one can vastly
increase the sensitivity and yield of capturing rare cell pop-
ulations from whole blood, while doing so in a gentle manner
that preserves the viability of isolated CTCs. Microfluidics is
an emerging multidisciplinary field in which engineering,
physics, chemistry, microtechnology, and biotechnology in-
tersect to create controlled nano-scale environments in which
biologic assays can be performed that are not possible at the
macro-scale.9 The ability to perform such novel microas-
says arises from the exploitation of differences in fluid
dynamic properties that result from manipulation of fluid
across microscopic distances in a rapid time frame at the
nano-scale compared with the macro-scale. Furthermore,
using microfluidic devices, researchers are able to create
better controlled microenvironments to manipulate cells,
and transport reagents.
The CTC-chip itself is a silicon chip the size of a
standard microscope slide on which an array of 78,000
m-sized posts are etched with a specific geometric pattern
and then are coated, or “functionalized,” with antibodies to
epithelial cell adhesion molecule (EpCAM). Whole blood
from patients is pneumatically pushed over the surface of
the CTC-chip and through the forest of microposts, Figure 1.
The fluid dynamics imposed by the geometric arrangement of
the posts leads the cellular component of the blood down
specific streamlines that are interjected frequently by the
posts, thereby maximizing interaction of the CTCs with the
EpCAM-functionalized surfaces, and resulting in high-effi-
ciency capture of the CTCs directly onto the sides of the
posts. The captured cells can then be confirmed as CTCs
(through staining which differentiates nonspecifically bound
leukocytes from epithelial CTCs), counted, and further ana-
lyzed in a variety of ways including molecular characteriza-
tion. Because the CTC-chip employs whole blood without
any preprocessing and the sheer stress experienced by CTCs
as they travel through the chip is minimal, 98% of captured
cells remain viable.7 The platform is flexible, in that different
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antibodies could potentially be used to functionalize the
microposts, resulting in the capacity to detect a wide variety
of types of CTCs.
We piloted the CTC-chip in 116 blood samples from 68
patients with epithelial cancer diagnoses, including 55 blood
samples from patients with advanced non-small cell lung
cancer (NSCLC).7 CTCs were isolated from all of the
NSCLC samples (mean 155 cells/ml, standard deviation
236). Similar results were also obtained among patients
with other tumor types, including colorectal, esophageal,
breast, and prostate cancer. Nine patients, including three
with advanced NSCLC, were followed with serial blood
samples for CTC analysis over the course of first or second-
line chemotherapy treatment and a significant correlation was
observed between the change in the quantity of CTCs cap-
tured and the response to treatment as measured by standard
CT scans using RECIST criteria, Pearson’s correlation coef-
ficient  0.68 (p  0.03).7
These findings are remarkable and distinguishable from
results obtained with other techniques in several ways, in-
cluding the high number of CTCs isolated per blood sample,
the ability to capture CTCs from essentially all patients
tested, and the capacity to dynamically monitor CTC quantity
in a meaningful way in real time. By way of comparison,
other investigators have studied the use of the immunomag-
netic bead-based CTC assay currently available for clinical
use (CellSearch, Veridex LLC) on 168 blood samples from
99 patients with advanced lung cancer; and detected CTCs in
34 (20%) of the samples.10 Only 10 (6%) of the lung cancer
samples had 6 CTCs/ml captured, the rest had lesser num-
bers of cells identified. Given the low sensitivity and low
yield of this method, we believe it may not prove as suitable
for monitoring response to treatment as the CTC-chip plat-
form, and studies are ongoing looking at the monitoring
capabilities of the CTC-chip in many cancer settings.
In addition to high sensitivity, an important advantage
of the CTC-chip is the ability to isolate cells while maintain-
ing their viability (98% of captured cells are viable7). In
contrast, the multiple-step process involved in the CellSearch
system renders isolated CTCs nonviable10 and therefore not
usable for potential future functional analyses. We believe
that the high capture rates and viable condition of the cells
isolated via CTC-chip make it an ideal tool for molecular
diagnostics.
In most types of cancer, cutting-edge, personalized
clinical care is becoming more dependent upon accurate
molecular diagnostic information. NSCLC is one of the prime
examples of this trend because somatic mutations in the
epidermal growth factor receptor (EGFR) gene are known to
correlate with increased response and survival after treatment
with tyrosine kinase inhibitors specific to the receptor.11–14
Several recent studies confirm the benefit of screening appro-
priate patients for EGFR mutations at the time of diagnosis
with advanced disease and making first-line therapy decisions
based on the results.14–17 The most notable of these is the
IPASS study, a large randomized trial that demonstrated that
using this strategy in never or low-smoking patients with
adenocarcinoma yields a superior outcome. When patients
with EGFR mutations were treated with first-line gefitinib,
the hazard ratio for progression-free survival was 0.48 (95%
confidence interval [CI] 0.36–0.68; p  0.0001) compared
with carboplatin and paclitaxel chemotherapy, and con-
versely when wild-type EGFR patients were treated with
first-line gefitinib, the hazard ratio for progression-free sur-
vival was 2.85 (95% CI 2.05–3.98; p  0.0001) compared
with chemotherapy. This suggests that specific genotype is a
more accurate predictor of benefit from anti-EGFR therapy
than clinical phenotype surrogates, and should be a crucial
component of first-line decision-making for a subset of
NSCLC patients.14 However, a practical limitation to this line
of work has been the feasibility of obtaining sufficient tumor
tissue to perform the genotype analyses in a time-frame that
is clinically useful. Furthermore, the development of acquired
resistance to EGFR tyrosine kinase inhibitors therapy is a
FIGURE 1. Illustrative cartoon demonstrating a patient with non-small cell lung cancer (NSCLC) donating a tube of peripheral
blood which is then processed in the circulating tumor cell (CTC)-chip immediately, without any required preprocessing. CTCs are
captured against the sides of the anti-Ep-CAM-coated posts (epithelial cell adhesion molecule), and then can be stained with fluo-
rescently-labeled markers for enumeration or undergo genomic DNA extraction for epidermal growth factor receptor mutation or
other molecular analysis.
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clinical issue about which we have some understanding of the
molecular basis (for example T790M EGFR mutations and
MET amplification), but additional research could be greatly
enhanced by removing the barrier of lack of repeated access
to tumor tissue.18–22
The CTC-chip may provide a solution to this problem.
In a group of NSCLC patients known to harbor EGFR
mutations, we compared direct sequencing of tumor tissue
biopsies for EGFR mutations with an allele-specific EGFR
mutation analysis of DNA from captured CTCs.8 We were
able to identify the expected EGFR mutation from CTCs in
92% of cases. In addition, in several patients followed serially
over the course of their therapy with gefitinib, we not only
documented the expected changes in CTC number correlating
to clinical and radiographic responses, but were able to
document the emergence of the T790M resistance mutation
heralding clinical resistance, suggesting that CTC analysis
could indeed be used as a pseudo repeat biopsy to look at
changing genotypes in response to targeted therapies. The
ability to perform noninvasive serial sampling of tumor
genotypes represents a sea-change in translational research
in NSCLC.
Although there is much work yet to be done to optimize
the uses of the CTC-chip, its ultimate implications for
NSCLC clinical management and research applications are
vast. Pilot results already show promise in monitoring re-
sponse to treatment in patients with advanced disease, which
could be translated to both standard clinical management and
clinical trials research. Given the controversy over the utility
and cost of radiographic screening for lung cancer, a blood-
based assay with high sensitivity like the CTC-chip is im-
mensely appealing as a screening tool for high-risk popula-
tions like smokers.23 The viability of the captured CTCs
makes their potential use in basic biologic research nearly
unlimited, with likely implications for understanding the
process of metastasis. And perhaps most timely, the proven
ability to analyze EGFR mutations by a peripheral blood
sample via the CTC-chip has crucial implications for the field
of targeted therapy and translational research.
In summary, the CTC-chip is a landmark technology
that allows for isolation of large numbers of rare CTCs from
the peripheral blood of cancer patients. The unique microflu-
idic platform holds promise for lung cancer research and
clinical management, and in the near future may be used for
early detection, monitoring of disease, and genotyping of
tumors.
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